INT141195

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 2006
Last Reported 2010
Negated 0
Speculated 3
Reported most in Body
Documents 14
Total Number 17
Disease Relevance 8.61
Pain Relevance 2.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Rela) nucleus (Rela) DNA binding (Rela)
protein complex (Rela) transcription factor binding (Rela) cytoplasm (Rela)
Anatomy Link Frequency
macrophage 1
epithelial cells 1
astrocytes 1
nucleus 1
Rela (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 109 99.26 Very High Very High Very High
Inflammation 200 99.08 Very High Very High Very High
Morphine 78 98.48 Very High Very High Very High
cINOD 30 94.32 High High
Antinociceptive 3 92.80 High High
antagonist 20 87.12 High High
rheumatoid arthritis 83 85.28 High High
cerebral cortex 1 84.96 Quite High
Hippocampus 2 84.28 Quite High
Osteoarthritis 17 81.12 Quite High
Disease Link Frequency Relevance Heat
Targeted Disruption 46 99.22 Very High Very High Very High
INFLAMMATION 239 99.08 Very High Very High Very High
Stress 211 98.72 Very High Very High Very High
Toxicity 157 98.64 Very High Very High Very High
Cancer 101 97.52 Very High Very High Very High
Apoptosis 96 96.40 Very High Very High Very High
Obesity 126 89.44 High High
Insulin Resistance 34 87.92 High High
Rheumatoid Arthritis 83 85.28 High High
Disease 60 82.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
B into the nucleus of astrocytes, while chelating Ca2+ with BAPTA significantly attenuates p65 (RelA) nuclear entry in vehicle (control), morphine, or Tat±morphine exposed astrocytes (Fig. 6).
Negative_regulation (attenuates) of RelA in astrocytes associated with morphine
1) Confidence 0.29 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2605563 Disease Relevance 0 Pain Relevance 0.78
B into the nucleus, the decrease in RelA mRNA might result in enhanced activation of NF?
Negative_regulation (decrease) of RelA mRNA in nucleus
2) Confidence 0.22 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526601 Disease Relevance 0.64 Pain Relevance 0.38
Furthermore, siegeskaurolic acid inhibited the nuclear factor-kappaB (NF-kappaB) activation induced by LPS, and this was associated with the prevention of inhibitor kappaB degradation (I kappaB), and subsequently with decreased nuclear p65 and p50 protein levels.
Negative_regulation (decreased) of p65
3) Confidence 0.15 Published 2007 Journal Eur. J. Pharmacol. Section Abstract Doc Link 17207792 Disease Relevance 0.38 Pain Relevance 0.23
In line with this we have shown that the expression of Nrf2 was reduced by the co-depletion of Keap1 and p65 (Fig. 7).
Negative_regulation (depletion) of p65
4) Confidence 0.13 Published 2010 Journal Biochemical Pharmacology Section Body Doc Link PMC2884179 Disease Relevance 0.47 Pain Relevance 0
Interestingly, the simultaneous depletion of p65 and Keap1 prevented the increase in basal levels of GSH (Fig. 5D) seen with Keap1 knock down only.
Negative_regulation (depletion) of p65 associated with targeted disruption
5) Confidence 0.13 Published 2010 Journal Biochemical Pharmacology Section Body Doc Link PMC2884179 Disease Relevance 0.54 Pain Relevance 0
The expression levels of p65 and p50, as two subunits of NF-?
Negative_regulation (levels) of p65
6) Confidence 0.10 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2668769 Disease Relevance 0.12 Pain Relevance 0
The protective effect of Nrf2 induction caused by the loss of Keap1 was reduced when p65 was depleted, implying a role for p65 as a modulator of Nrf2-dependent cell protection.
Negative_regulation (depleted) of p65
7) Confidence 0.10 Published 2010 Journal Biochemical Pharmacology Section Body Doc Link PMC2884179 Disease Relevance 0.56 Pain Relevance 0
RNAi depletion of Nrf2 and Keap1, but not p65, influences the basal level of GSH in hepa-1c1c7 cells
Negative_regulation (depletion) of p65
8) Confidence 0.10 Published 2010 Journal Biochemical Pharmacology Section Body Doc Link PMC2884179 Disease Relevance 0.63 Pain Relevance 0
In this study, we used RNAi to investigate the physiological and molecular effects of Keap1, Nrf2 and p65 silencing on cellular cytoprotection.
Spec (investigate) Negative_regulation (effects) of p65
9) Confidence 0.10 Published 2010 Journal Biochemical Pharmacology Section Body Doc Link PMC2884179 Disease Relevance 0.07 Pain Relevance 0
LDH assays indicated that RNAi knock down of Keap1 (Fig. 5A) protects the cells against DNCB toxicity and shows that DNCB toxicity was augmented when Nrf2 was depleted with RNAi directed against Nrf2 (Fig. 5B) and p65 was depleted (Fig. 5C) individually.
Negative_regulation (depleted) of p65 associated with targeted disruption and toxicity
10) Confidence 0.10 Published 2010 Journal Biochemical Pharmacology Section Body Doc Link PMC2884179 Disease Relevance 0.63 Pain Relevance 0
Interestingly, the phenotypic effect of the Keap1 knock down was reversed when both Keap1 and p65 (Fig. 5D) were depleted simultaneously.
Negative_regulation (depleted) of p65 associated with targeted disruption
11) Confidence 0.10 Published 2010 Journal Biochemical Pharmacology Section Body Doc Link PMC2884179 Disease Relevance 0.67 Pain Relevance 0
Therefore, we examined if the depletion of Keap1, Nrf2 and p65 has any effect on the basal level of GSH thus further influencing the cellsÂ’ ability to defend against electrophile toxicity.
Spec (examined) Negative_regulation (depletion) of p65 associated with toxicity
12) Confidence 0.10 Published 2010 Journal Biochemical Pharmacology Section Body Doc Link PMC2884179 Disease Relevance 0.49 Pain Relevance 0
B p65 subunit has been experimentally blocked in airway epithelial cells by small interfering (si)RNAs, which in vitro reduced the expression of both IL-6 and IL-8 (de Boer 2005).
Negative_regulation (blocked) of p65 in epithelial cells
13) Confidence 0.05 Published 2006 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2707155 Disease Relevance 0.63 Pain Relevance 0.25
When we investigated the possible involvement of NFkB signaling suppression in D6 antiproliferative activity we found out that our cell lines did not show constitutive activation of this transcription factor so that probably this pathway is not involved in the transformation processes of these cells (see Additional file 3 Figure S2).
Spec (investigated) Negative_regulation (suppression) of NFkB
14) Confidence 0.04 Published 2010 Journal Mol Cancer Section Body Doc Link PMC2898702 Disease Relevance 0.81 Pain Relevance 0
Several reports have demonstrated that luteolin inhibits pro-inflammatory cytokine expression in various cell types by blocking NFkB (reviewed in [28]).
Negative_regulation (blocking) of NFkB associated with inflammation and cytokine
15) Confidence 0.04 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2819254 Disease Relevance 0.31 Pain Relevance 0.20
Inactivation of the inhibitor of NFkB kinase beta (IKK2), the main activator of TNF-?
Negative_regulation (inhibitor) of NFkB
16) Confidence 0.04 Published 2010 Journal PLoS Genetics Section Body Doc Link PMC2865520 Disease Relevance 1.42 Pain Relevance 0.24
In their study, Idris and co [64] reported the ability of HCT1026 to inhibit receptor activator of NFkB (RANKL), as well as RANKL-induced activation of NFkB and ERK pathway in LPS-stimulated macrophage cultures.
Negative_regulation (inhibit receptor activator) of NFkB in macrophage
17) Confidence 0.03 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC3000390 Disease Relevance 0.23 Pain Relevance 0.36

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox